New Glaucoma Drug Begins Clinical Trials

New Glaucoma Drug Begins Clinical Trials - College of Pharmacy

Thanks to a research collaboration between the Institute for Therapeutics Discovery & Development and Mayo Clinic, a drug that shows promise ...

FDA Approves First-of-its-Kind Glaucoma Treatment

The U.S. Food and Drug Administration has approved a new treatment for glaucoma, iDose® TR (travoprost intracameral implant, 75 mcg).

Glaucoma drug shows promise against neurodegenerative diseases ...

They discovered that drugs known as carbonic anhydrase inhibitors – of which the glaucoma drug methazolamide is one – clear tau build-up and ...

Glaucoma Gene Therapy Moves Toward Clinical Trials with New ...

Vivek Gupta from Macquarie Medical School in Australia will conduct the research necessary to bring Gupta's retinal gene therapy—a novel, ...

FDA approves Skye Bioscience's IND for glaucoma therapy trial

The clinical trials include a Phase II study to treat primary open angle glaucoma or ocular hypertension (OHT), which is scheduled to begin in ...

New glaucoma medications: latanoprostene bunod, netarsudil, and ...

Alpha adrenergic agonists and carbonic anhydrase inhibitors are other classes of drugs that aid in lowering of IOP pharmacologically. Clinical trials showing ...

Novel Glaucoma Medications: From Clinical Trials to ... - MillennialEYE

The year 2017 saw the much-anticipated release of two new medical glaucoma therapies after a long period of quiescence dating back to the release of ...

Novel Glaucoma Medications: From Clinical Trials to Clinical ...

The year 2017 saw the much-anticipated release of two new medical glaucoma therapies after a long period of quiescence dating back to the release of ...

An overview of new glaucoma medications - EyeWorld

“Vyzulta [latanoprostene bunod, Bausch + Lomb] in November 2017, Rhopressa [netarsudil, Aerie Pharmaceuticals] in December 2017, and Rocklatan, the fixed-dose ...

The Glaucoma Medication Pipeline, 2022 - Review of Ophthalmology

The PGA that has shown promise in clinical trials thus far is NCX 470, formed from a nitric oxide-donating compound. A previous animal study ...

Intraocular Drug Delivery Systems in Glaucoma

Interim results from a phase 2a study conducted in Australia and New Zealand demonstrated a sustained >20% reduction of IOP after 6 months with ...

Glaucoma Drug Clinical Trials Offer Promising Results | Pharmacy

The results of Phase 2 clinical trials for glaucoma drug QLS-101 have demonstrated a favorable safety and tolerability profile, according to ...

Sustained Release Glaucoma Delivery Systems - EyeWiki

Sustained release glaucoma therapy is a burgeoning area of need and study. There are currently two FDA-approved modalities with several ...

New Drugs and Delivery Options in Glaucoma

In randomized clinical trials, the latanoprost emulsion was shown to reduce IOP in patients with open-angle glaucoma and ocular hypertension by a mean 6 mm Hg ...

Skye Bioscience Receives Clinical Site Approvals for Glaucoma ...

Site initiation visits for the Phase 2a study will commence in October. Skye plans for patient enrollment to begin in Q4, with an interim ...

Santen Receives FDA Approval For Omlonti For Primary Open ...

The new glaucoma eye drop medication increases drainage through the eye's conventional outflow pathways via a unique pharmacological action.

Drug Delivery Platform Developed by CU Ophthalmologist Shows ...

After six months of in-human study, SpyGlass is reducing intraocular pressure and allowing patients to forgo topical therapies. ... A new drug ...

Two New Glaucoma Medications: Learn More

Clinical trials have been conducted comparing Vyzulta to latanoprost and timolol. Vyzulta results in greater eye pressure lowering compared to ...

Eye-opening research: NIH funds glaucoma treatment research at S&T

The new formulation will deliver more than one type of medication, Yang says. The medications will work to drain blockages in the eyes, while ...

Glaucoma Clinical Research: Trends in Treatment Strategies and ...

A new class of glaucoma drugs and the first major innovation in glaucoma therapy after 2000s were signaled by the approval of the first Rho kinase inhibitors ...